Quantitative digital image analysis of somatostatin receptor 2 immunohistochemistry in pancreatic neuroendocrine tumors

Immunohistochemical analysis of somatostatin receptor 2 (SSTR2) provides important information regarding the potential therapeutic efficacy of somatostatin analogues (SSAs) in patients with neuroendocrine tumors. HER2 scoring has been proposed to interpret SSTR2 immunoreactivity but their reproducib...

Full description

Saved in:
Bibliographic Details
Published in:Medical molecular morphology 2021-12, Vol.54 (4), p.324-336
Main Authors: Watanabe, Hirofumi, Ide, Rioko, Yamazaki, Yuto, Fujishima, Fumiyoshi, Kasajima, Atsuko, Yazdani, Samaneh, Tachibana, Tomoyoshi, Motoi, Fuyuhiko, Unno, Michiaki, Sasano, Hironobu
Format: Article
Language:English
Subjects:
Anatomy
ErbB-2 protein
Humans
Image processing
Immunohistochemistry
Insulinoma
Medicine
Medicine & Public Health
Molecular Medicine
Neuroendocrine tumors
Neuroendocrine Tumors - diagnostic imaging
Neuroendocrine Tumors - drug therapy
Optical density
Original Paper
Pancreas
Pancreatic cancer
Pancreatic Neoplasms - drug therapy
Pathology
Receptors, Somatostatin
Reproducibility of Results
Somatostatin
Somatostatin receptors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immunohistochemical analysis of somatostatin receptor 2 (SSTR2) provides important information regarding the potential therapeutic efficacy of somatostatin analogues (SSAs) in patients with neuroendocrine tumors. HER2 scoring has been proposed to interpret SSTR2 immunoreactivity but their reproducibility was relatively low because of its intrinsic subjective nature. Digital image analysis (DIA) has recently been proposed as an objective and more precise method of evaluating immunoreactivity. Therefore, in this study, we used DIA for analyzing SSTR2 immunoreactivity in pancreatic neuroendocrine tumors (PanNETs) to obtain its H score and “(%) strong positive cells” and compared the results with those of manually obtained HER2 scores. Membranous SSTR2 immunoreactivity evaluated by DIA was calculated by two scales as: “Membrane Optical Density” and “Minimum Membrane Completeness”. PanNETs with HER2 score of > 2 demonstrated the highest concordance with results of “(%) strong positive cells” obtained by DIA when “Minimum Membrane Completeness” was tentatively set at 80%. The SSTR2 immunoreactivity, evaluated based on all scoring systems, was different between grades G1 and G2 in insulinoma but not in non-functional PanNETs. DIA provided reproducible results of SSTR2 immunoreactivity in PanNETs and yielded important information as to the potential application of SSAs.
ISSN:1860-1480
1860-1499
DOI:10.1007/s00795-021-00294-6